Recent Updates
Recently added Catalysts

Evoke Pharma, Inc.

EVOK
Fair ValuePharma · Commercial
FDA catalysts, PDUFA dates & pipeline intelligence
$11
▲ +0.02 · +0.18%

Last traded Dec 16, 2025. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full EVOK financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.9452W HIGH $11.00
Volume
47.10 K
Value Traded
517.67 K
Short % Float
0.75%
+0.73%Week
+3%1 Month
+116.96%3 Month
+291.46%6 Month
-97.22%5 Year
-99.32%All Time

Cash Data

Unlock EVOK cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
18.95 M
EPS (TTM)
-2.38
P/E Ratio
-
Ent. Value
12.48 M
Total Shares
1.56 M
Float Shares
1.46 M
Insiders
5.44%
Institutions
16.22%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every EVOK catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

EVOK Catalyst Timeline

Dated clinical, regulatory and corporate events for Evoke Pharma, Inc.

Unlock the full EVOK catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How EVOK actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2019-04-02Gimoti (metoclopramide nasal spray) PDUFA Date CRLPDUFA
Unlock all EVOK historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D25 / 100
Pipeline Score
$4M
Pipeline Value
$14M
Commercial Value
Fair Value
Valuation Signal
1
Drugs Scored
0.8x
rNPV / MCap
Evoke Pharma, Inc. faces pipeline headwinds (25/100), with $86M risk-adjusted pipeline value, led by Sacrosidase in Fructan Intolerance (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Sep 2025) Revenue $14.4M x 1.0 = $14M
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Sacrosidase Small moleculeCompletedNCT05703009Fructan IntolerancePhase 2 COMPLETED 25Jan 22, 2024
Unlock the EVOK pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every EVOK program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
GIMOTI diabetic gastroparesis2023-10-31the likelihood of a DGP patient treated with GIMOTI visiting the ED or being admitted to the hospital was less than half that of patients treated with OMCPRead MoreEvoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023Read More
Scroll for more · summaries link to the source press release
Unlock every EVOK trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock EVOK insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Klein Roger M.10% OwnerSell -5,000 29,000 held$10.66 11/06/2025
Unlock the full EVOK insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in EVOK

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in EVOK for Q2 2026.
Unlock every fund holding EVOK
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in EVOK
Shares held by hedge funds each quarter, and who bought or sold.

EVOK Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock EVOK option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live EVOK option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock EVOK options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How EVOK ranks across every disease it competes in

Competitive Position is a premium feature
See how EVOK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

EVOK News

About Evoke Pharma, Inc.

Founded2013
BIOPHARMAWATCH ELITE PLUS
Trade the next EVOK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime